COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
30/07/2024
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut [...]
DBV Technologies présente les dernières avancées du programme Viaskin Peanut chez les enfants de 4 à 7 ans et les tout-petits de 1 à 3 ans et publie ses résultats financiers du deuxième trimestre et premier semestre 2024.
30/07/2024
DBV Technologies présente les dernières avancées du programme Viaskin Peanut chez les enfants de 4 à 7 ans et les tout-petits de 1 à 3 ans et publie ses résultats financiers du deuxième trimestre et premier semestre [...]
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
30/07/2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that it will report its second quarter 2024 financial results before the market opens [...]
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
30/07/2024
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical [...]
MacroGenics Provides Vobramitamab Duocarmazine Update
30/07/2024
Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in September ESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of [...]
Inari Medical Announces Chief Financial Officer Retirement and Succession Plan
30/07/2024
Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company [...]
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
30/07/2024
ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ [...]
FibroGen to Report Second Quarter 2024 Financial Results
30/07/2024
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference [...]
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
30/07/2024
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024
30/07/2024
FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2024 after [...]
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
30/07/2024
SOUTH SAN FRANCISCO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]
Glass House Brands to Host Second Quarter 2024 Conference Call on August 13, 2024
30/07/2024
LONG BEACH, Calif. and TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company” (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest- [...]
Inari Medical Reports Second Quarter 2024 Financial Results
30/07/2024
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
30/07/2024
SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that it will release its second quarter 2024 [...]
Iridex to Report Second Quarter 2024 Financial Results on August 8, 2024
30/07/2024
MOUNTAIN VIEW, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
30/07/2024
Pamrevlumab arm of the Precision Promise SM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as [...]
Stryker reports second quarter 2024 operating results
30/07/2024
Portage, Michigan, July 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2024: Second Quarter Results Reported net sales increased 8.5% to $5.4 billion Organic net [...]
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
30/07/2024
Confirming cash runway guidance into 2026 ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and [...]
Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024
30/07/2024
HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]

Pages